Okamoto is Japan’s leading marketer of condoms with approximately 60% share of the Japanese condom market. The value of the Japanese condom market has been estimated to be in the order of US$500 million. Okamoto, based in Tokyo, has total revenues of more than US$740 million and over 1,500 employees. In addition to its dominant position in the Japanese condom market, Okamoto also holds strong market positions in several other Asian markets, including Korea, Taiwan, Malaysia, Singapore and China.
Okamoto’s senior managing director Mr. Seiji Takeuchi said in January this year that condoms with functional coatings and gels represent the next wave of innovation in the Japanese condom market following on from a decades-long focus on condom thinness.
Following this initial VivaGel®-coated condom certification, Mr Takeuchi said, “We are very pleased to be in a partnership with Starpharma for this product.”
Starpharma has a separate licensing agreement with Ansell Limited (ASX: ANN) which provides marketing rights to a VivaGel®-coated condom in countries outside Japan and the company looks forward to further regulatory approvals under that partnership.
Melbourne, Australia; Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that regulatory certification has been granted for marketing Starpharma’s VivaGel®-coated condom in Japan, the world’s second largest condom market.
VivaGel® is licensed to Okamoto Industries (TSE: JP3192800005) as a condom coating for the Japanese market. Okamoto is the market leader for condoms sold in Japan and has held this position for many years. Under Starpharma’s commercial licence agreement with Okamoto, Okamoto has exclusive Japanese marketing rights for the VivaGel®-coated condom. VivaGel®-coated condoms sold by Okamoto will carry the VivaGel® brand and Starpharma will receive royalties based on sales of these condoms.
“This receipt of the world’s first marketing approval for a VivaGel®-coated condom in Japan marks a major milestone for this product and for our strategically important partnership with Okamoto. We greatly appreciate Okamoto’s support and assistance in achieving this certification and we look forward to a long and mutually profitable commercial relationship” said Starpharma CEO, Dr Jackie Fairley.
“Following this certification Starpharma looks forward to the introduction of its innovative, patented VivaGel®-coated condom to this key market in partnership with Okamoto, one of the world’s leading condom companies,” she added.
In 2013, McEwen Mining and Hochschild Mining, entered into an agreement to contribute their respective exploration properties around the mine to the San José joint venture (see Figure 4). For much of 2013, the exploration program at San José focused on the geological mapping of the district area, identifying new structures located south and southeast of the property. A total of approximately 10,529 metres of drilling was completed during the year.
Table 1 - San José Mineral Resource Estimate, December 31, 2013
(K oz) Ag
Measured 1,524 8.85 640 433.6 31.36
Indicated 2,874 6.71 448 620.0 41.40
Measured and Indicated 4,398 7.45 515 1053.6 72.76
Inferred 1,852 7.23 455 430.5 27.09
Represents 100% of the resources. McEwen Mining Inc. has a 49% attributable interest in the San José mine.
Mineral resources, which are not mineral reserves, do not have demonstrated economic viability.
Mineral resources are reported inclusive of mineral reserves.
The quantity and grade of reported Inferred resources are uncertain in nature and there has been insufficient exploration to classify these Inferred resources as Measured or Indicated, and it is uncertain if further exploration will result in upgrading them to an Indicated or Measured category.
Mineral Resources were estimated by Hochschild Mining Plc using the CIM Standards on Mineral Resources and Reserves, Definitions and Guidelines prepared by the CIM Standing Committee on Reserve Definitions. P&E Mining Consultants Inc have audited the resource estimates and found that they meet both the requirements for Canadian disclosure under NI 43-101.
Resource estimations utilized inverse distance and ordinary kirging methods depending upon data density.
Metal prices used were $1200/oz for Au and $20/oz for Ag.
Resources were defined at a cut-off grade of 215 g/t AgEq, which is equivalent to a cut-off value of $94.76/tonne.
SAN JOSÉ MINE – SOLID GROWTH CONTINUES
Production for 2013 increased by 10%, to 221,073 gold equivalent ounces (converting silver into gold using a 52:1 ratio), consisting of 98,827 gold ounces and 6,356,801 silver ounces (see Figure 1). Production attributable to McEwen Mining for 2013 was 108,326 gold equivalent ounces, consisting of 48,425 ounces of gold and 3.1 million ounces of silver. Net of this production, total reserves increased by 12% for gold and 12% for silver, to an estimated 1.8 million tonnes at a grade of 7.03 gpt gold and 515 gpt silver, for a total of 409,400 ounces of gold and 30.1 million ounces of silver (see Figure 2). Gold grades increased by 9% to 7.03 gpt and silver grades increased by 10% to 515 gpt.
In addition to increasing reserves, the exploration program in 2013 was focused on finding extensions of the known resource while also upgrading the resource previously classified as Inferred. The mine is consistently replacing production within the Measured and Indicated resource categories. The contained ounces of gold and silver within the 4.4 million tonnes of the Measured and Indicated resources are up from 2012 by 6% and 7% respectively for a total of 1.05 million ounces gold and 72.8 million ounces silver (see Figure 3). Gold and silver grades both increased by 6% to 7.45 gpt gold and 515 gpt silver.
Inferred gold and silver resources were down as a result of the increase in the Measured and Indicated resources versus 2012, with Inferred resources totaling 1.9 million tonnes at a grade of 7.23 gpt gold and 455 gpt silver, for a total of 430,500 ounces of gold and 27.1 million ounces of silver, representing a decrease of 13% for gold and 16% for silver from 2012. Gold grades decreased by 2% to 7.23 gpt and silver grades decreased by 4% to 455 gpt.
The San José mine is owned and operated by Minera Santa Cruz S.A., a joint venture owned 51% by Hochschild Mining Plc and 49% by McEwen Mining Inc.
McEwen Mining Inc. (NYSE: MUX) (TSX: MUX) is pleased to announce an updated mineral reserve and resource estimate for the San José mine (49% owned by McEwen Mining), located in Santa Cruz province, Argentina. The updated estimate continues to demonstrate that San José is one of the highest-grade precious metal mines in the Americas that continues to replace its mined ounces even with record production. The mineral reserve and resource estimates were calculated using US$1,200 per ounce gold and US$20 per ounce silver. The estimates were independently audited by P&E Mining Consultants Inc.
San José Mine Reserve & Resource Highlights (100% Basis)
Proven and Probable gold and silver reserves increased by 12% and 12% respectively, to 409,400 ounces gold and 30.1 million ounces silver, contained in 1.8 million tonnes. Gold grades increased by 9% to 7.03 gpt and silver grades increased by 10% to 515 gpt.
Measured and Indicated gold and silver resources increased by 6% and 7% respectively, with 1.05 million ounces gold and 72.8 million ounces silver, contained in 4.4 million tonnes. Gold and silver grades increased by 6% to 7.45 gpt gold and 515 gpt silver.
Inferred gold and silver resources were down slightly from 2012 with 430,500 ounces gold and 27.1 million ounces silver, contained in 1.9 million tonnes. Gold grades decreased by 2% to 7.23 gpt and silver grades decreased by 4% to 455 gpt.
We still have quite a distance to go and if interest rates were to go up, the cost of servicing the debt is going to cripple governments and send shockwaves around the world.
As for manipulation, it has been the mandate of central banks around the world to manage their money, and they have a lot of tools at their disposal, such as the Federal Reserve's saying, "Interest rates are going to be here -- 50 or 100 basis points -- and locked there for a period of time."
They have all sorts of levers they can move around and one of those would be metals prices. It's quite reasonable to expect that the central banks are going to be in there trying to manage the economy of the world, and metals prices would be one of those areas.
There have been a number of very good attempts -- GATA is one -- to highlight what they believe is manipulation that goes beyond the mandate of central banks. They have raised the awareness of it but that hasn't changed the habits of government. I would say the governments are thinking that they're doing it for the good of the country and they can do anything they want. I think making a comment to our central bank about it would be like pouring water on the back of a duck, unfortunately.
The market will catch up with this. The Federal Reserve is saying that it is going to keep rates fixed for a period of time. Maybe they can do it in the short term but history suggests that over the intermediate and long term it's impossible to hold certain parts of the economy together in static. There are lots of dynamics out there and you're starting to see metals prices improving, and I'm quite encouraged by the firming I'm seeing in prices right now.
There's a complancency in the broad market with people believing that all the issues that brought about the collapse a few years back have been dealt with, and that's far from the truth. But it's an easier thing to believe and a more pleasant way to look at the world than to look at $17 trillion-plus of debt by the United States alone and to take that out over the whole world.
Its funny cause they let me post it on the AEMD board, but I tried 3 times to post here and it was rejected. (made sure there were no links)
In additional comments to Agence France-Presse, Brentjens said, "Basically, what we do is re-educate the T cell in the laboratory with gene therapy to recognize and now kill tumor cells."
Following 15 years of study on the procedure, Brentjens said that "it seems to really work in patients with this particular type of cancer."
Of the 16 patients who took part in the study, 14 achieved total remission. But, Agus said, the treatment does not cure cancer on its own.
"What we know is this cancer comes back and the only way to cure it is with a bone marrow transplant," he said. "You can only go for a bone marrow transplant if you've first eliminated the cancer cells in the blood."
The research oncologist said the therapy was able to remove cancer cells from the blood effectively, and that "most of the patients were able to go on to transplant." At that point, he said, patients can actually be cured of the disease.
'Treatment might work too well'
Some of the biggest problems with current cancer treatments such as chemotherapy are the side effects: The drugs involved in chemotherapy can make patients very sick and weak. And while Agus said all treatments will have some side effects, the new therapy might actually work "too well."
"These cells kill all of the cancer at once and it's actually the toxins from the dead cancer cells that cause the side effects," he said, adding that, since the initial success among the 16 patients, between 60 and 80 in the U.S. have signed onto trials, which are also being launched in Europe.
The oncologist said the breakthrough treatment was not possible even a decade ago, because it was built on years of prior trial-and-error involving gene therapy.
At present, the therapy has not been approved by the U.S. Food and Drug Administration. Agus said the treatment can cost upwards of $100,000 per patient, but he said that cost should decrease as the therapy advances.
Seems as if Sloan Kettering has found a way to kill Leukemia cells in the blood. Read to the end, the only side effect seems to be that it works so well, and kills the cells all at once, so the release of toxins becomes a problem.... I believe thats exactly where WE (AEMD and CTSO) come in! :
A revolutionary breakthrough in cancer treatment that is being described as a "game-changer" would see the body's own immune system utilized to attack diseased cells, rather than rely on sickening chemotherapy, researchers announced lately.
Scientists at Memorial Sloan Kettering Cancer Center in New York say they have successfully experimented with the new procedure, using 16 people who had advanced leukemia and had otherwise run out of treatment options. The researchers said the patients underwent targeted T cell therapy, which then eliminated the cancerous cells in most of the patients, CBS News reported.
Dr. David Agus, a CBS News expert contributor who leads the Westside Cancer Center at the University of Southern California, called the team's work "remarkable research."
'This was no fluke'
"They took 16 patients with advanced leukemia, who had failed chemotherapy or not responded at all to chemotherapy, so they classically have weeks to months to live. They took their own immune cells out... and inserted a homing mechanism to target the cancer cells," said Agus. "The cancer cells were growing on their own, unrelentingly, and these immune cells came in and they could target and kill them. They become assassins. So, making their own immune cells become assassins and it worked."
Study senior author Dr. Renier Brentjens, an oncologist at Memorial Sloan Kettering, told HealthDay News: "First and foremost, we've shown that this isn't a fluke. This is a reliable result. ... We're still very much in the early stages of development. ... [T]his is potentially the first promising new therapy [for advanced B-cell ALL] in a long time."
News hit multiple sources and a few 'stock picking' sites have taken notice, may explain the volume and movement of late (besides all of the actual good news we've recently gotten and progress we've made of course) :
From Baystreet -
Meanwhile, Aethlon Medical Inc.’s (OTCQB: AEMD) shares soared Mar. 7, with 570,832 shares changing hands, significantly more than its three-month average of 345,162 shares.
The uptick in volume appears to be tied to a Mar. 5 announcement that the San Diego-based medical device company’s researchers have successfully isolated brain-specific biomarkers associated with a variety of neurodegenerative disorders.
The discoveries could have implications in the diagnosis, monitoring and treatment of Alzheimer's Disease (AD), Chronic Traumatic Encephalopathy (CTE) and Traumatic Brain Injury (TBI). Aethlon Medical develops therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions. ESI develops exosome-based solutions to diagnose and monitor acute and chronic conditions.
On Mar. 7, AEMD’s share price closed at 21 cents, down 1 cent from its close of 22 cents the previous day.
Yesterday, however, we saw a bit more attention, but that might be the reason why AEMD made a smaller 10% jump after opening gapped up at $0.25. The interest and the big volume that generated $543 thousand in trade value were probably why the ticker began to slide and closed the session with a price of $0.218.
The company has also filed for a provisional patent entitled, "Brain Specific Exosome Based Diagnostics and Extracorporeal Therapies", however, there will be some time until we would be able to see if it is approved.
This leaves the stock in a situation where it might go in any direction, depending on near-future press releases. Still, the company is one of the few medical ventures in the OTC markets that has some revenue through government contracts, even though it was operating at a $2.2 million net loss in the quarterly period ended December 31, 2013.
An of course, just like everytime, it will be a good idea to do your due diligence before you make an investment decision.
Looks like some stock site wrote something about us:
Aehtlon Medical, Inc. (OTCBB:AEMD, AEMD message board) is one of those medical companies in the OTC markets whose stock rarely gets high dollar volume. The ticker has been descending the charts from the beginning of the year, but things have changed in the past sessions.
On March 5, the company made a press release announcing a discovery they have made that might help identify and cure chronic traumatic encephalatopathy (CTE), which can be only diagnosed postmortem at the moment, and help patients with traumatic brain injury, Alzheimer's and other neurodegenerative disorders.
They say that they have isolated brain-specific biomarkers associated with neurodegenerative disorders with their subsidiary Exosome Sciences, Inc. that may prove to be life-saving for patients. This led to an immediate reaction in the stock market.
The company stock rarely makes percentile movements bigger than 5%, but it managed to get a good 19% gain in the same day the news were announced. The volume wasn't high and generated only $164 thousand in trade value.
Melbourne, Australia; Starpharma (ASX: SPL, OTCQX: SPHRY) today announced it has received the anticipated $4.7M of R&D tax incentive relating to FY13 expenditures, following the lodgement of the Company’s annual income tax return.
The R&D tax refund relates to eligible Australian R&D expenditure, and previously announced overseas findings relating to Starpharma’s VivaGel®, and DEP™ docetaxel clinical programs.
Commenting on the refund, Starpharma CEO Dr Jackie Fairley said:
“The R&D tax incentive allows Starpharma to confidently advance development of its proprietary products including the clinical programs for VivaGel® and DEPTM docetaxel. In the case of DEP™ docetaxel, it supports the conduct of the clinical trial in Australia with the additional benefit that Australian patients will be the first in the world to have access to Starpharma’s improved version of the widely used cancer drug, docetaxel.”
What part of:
...............................".( Increasing orders and REORDERS )".........................
didn't you get?
Therapeutic Application and Patent Application
The development of a therapeutic device that targets selective elimination of circulating beta-amyloid and tau is supported by the “peripheral sink” theory, which postulates that the reduction of these particles from systemic circulation promotes deplaquing from the brain. Thus, inhibiting the continued progression of neurodegenerative processes. Aethlon and ESI further disclosed the subsequent filing of a provisional patent entitled, “Brain Specific Exosome Based Diagnostics and Extracorporeal Therapies.”
“With the exosome-based technologies developed by our group, we are at the verge of breakthroughs for the management and treatment of brain injuries and diseases that have been associated with disability and death,” stated Dr. Cicek Gercel-Taylor, Clinical Research Director at ESI.
Circulating biomarkers have been proposed for the definitive diagnosis and monitoring treatment of brain injuries. The approach would enable diagnosing the condition, identifying processes that are difficult to image, monitoring responses to interventions, and predicting those who are at risk for long-term neurologic consequences. However, circulating biomarkers such as free protein and nucleic acids are extremely unstable in circulation, thus a high steady-state must be reached for detection, which is generally not observed except in severe cases. To circumvent these issues, exosome-associated biomarkers can be utilized as they are stable and detectable in the circulation.
“An exosome-based liquid biopsy that could identify the early onset of Alzheimer’s disease or CTE in a living person may also unlock the ability to monitor disease progression and set the stage for new therapeutic advances, which could include Aethlon Medical therapeutic devices,” stated Jim Joyce, CEO of Aethlon Medical and Executive Chairman at Exosome Sciences.
AD is the most common form of dementia. There is no cure for the disease, which worsens as it progresses, and eventually leads to death. Beta-amyloid plaques and neurofibrillary tangles have long been recognized as a common pathologic hallmark of AD. In 2010, it was estimated that 36 million people worldwide were living with AD.
“This advancement represents a new paradigm for brain injuries. In addition to providing definitive diagnosis, the proteomic and transcriptomic characterization of exosomes isolated specifically from the brain will provide a window into the molecular mechanisms underlying acute and chronic brain injuries,” stated ESI Chief Scientific Officer, Dr. Douglas Taylor.
As a result of the discoveries, brain-derived exosomes can be specifically isolated and the protein and RNA cargoes identified. In studies of brain tissue, specific RNAs have been associated with development of neurological disorders, contributing to the onset and progression of brain injuries. Exosomal RNA and protein cargoes represent surrogates to brain biopsies and have utility as stable, clinically accessible biomarkers for brain injury detection, stratification of patients and therapeutic outcomes.